en · de · es · fr · pt
peptide-index.peptides1126.com › Blog › Bpc-157 Origin And Structure — Hands-On Walkthrough

Bpc-157 Origin And Structure — Hands-On Walkthrough

By Editorial Desk · published 2026-05-17 · last reviewed 2026-07-09 · Blog

The short version of Pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-07-09. Anything still debated is marked as such rather than presented as settled.

BPC-157 Origin and Structure

BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.

Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.

Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.

Background, Origin, and Naming

Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.

Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.

BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

Bpc-157 at a glance

PropertyValueNotes
Molecular classSynthetic pentadecapeptideComposed of fifteen amino acid residues
Amino acid sequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-ValSingle-letter form GEPPPGKPADDAGLV
Original sourceFragment of a protein in human gastric juiceFirst characterized in the 1990s
Number in name157Refers to the fragment's position in the source protein
Human trial evidenceLimitedPreclinical rodent data predominate

Identity and Molecular Background

The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.

BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.

Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.

Related pages on this site

Handling, Stability, and Analysis

Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.

Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.

Further detail

=== Synthesis === Loperamide is synthesized starting from the lactone 3,3-diphenyldihydrofuran-2(3H)-one and ethyl 4-oxopiperidine-1-carboxylate, on a lab scale. On a large scale a similar synthesis is followed, except that the lactone and piperidinone are produced from cheaper materials rather than purchased.

TL 2636 (M-125) is an opioid drug derived from thebaine, one of the bridged oripavine family of drugs known as the Bentley compounds which includes drugs such as buprenorphine and etorphine. TL 2636 is closely related to etorphine and is a similarly potent opioid analgesic and sedative, but at low doses is characterised by producing pronounced nausea and vomiting, with a long duration of action. It was investigated as a potential incapacitating agent but was not successful due to a poor therapeutic index.

=== Economic and social cost === Addiction imposes substantial financial and human costs on individuals and on society. These costs arise from the direct adverse effects of drugs and associated healthcare costs (e.g., emergency medical services and outpatient and inpatient care), long-term complications (e.g., lung cancer from smoking tobacco products, liver cirrhosis and dementia from chronic alcohol consumption, and meth mouth from methamphetamine use), the loss of productivity and associated welfare costs, fatal and non-fatal accidents (e.g., traffic collisions), suicides, homicides, and incarceration, among others. In the United States, an estimated 69,973 people died of drug overdose in 2025, down almost 14% from 81,313 in 2024 and the third consecutive annual decline following the peak reached during the opioid epidemic. Access to treatment is limited worldwide: among countries reporting data to the World Health Organization, the proportion of people with a substance use disorder in contact with treatment services ranged from under 1% to no more than 35%.

== Kinetics == The kinetics and rates of step-growth polymerization can be described using a polyesterification mechanism. The simple esterification is an acid-catalyzed process in which protonation of the acid is followed by interaction with the alcohol to produce an ester and water. However, there are a few assumptions needed with this kinetic model. The first assumption is water (or any other condensation product) is efficiently removed. Secondly, the functional group reactivities are independent of chain length. Finally, it is assumed that each step only involves one alcohol and one acid.

Sources: en.wikipedia.org

Background from the literature

Head of State: The ceremonial head of the state and civilian commander-in-chief of the Pakistan Armed Forces is the President, elected by an Electoral College. The prime minister advises the president on key appointments, including military and judicial positions, and the president is constitutionally bound to act on this advice. The president also holds powers to pardon and grant clemency. Legislative: The bicameral legislature includes a 96-member Senate (upper house) and a 336-member National Assembly (lower house). National Assembly members are elected via first-past-the-post under universal adult suffrage, representing National Assembly constituencies. The constitution reserves 70 seats for women and religious minorities, allocated to political parties based on proportional representation. Senate members are elected by provincial legislators, ensuring equal representation across all provinces.

== Research == BPC-157 was discovered by Predrag Sikiric, a researcher in Zagreb, Croatia who published it in 1993 in Journal of Physiology, Paris. Pre-clinical research has indicated that BPC-157 may have cytoprotective, neuroprotective, and anti-inflammatory effects, and may also accelerate tissue and organ healing. This substance is sometimes used in functional medicine despite not being approved by any drug regulatory agency. The compound promotes angiogenesis and as a result has some concerns over cancer promotion. As of 2022, the peptide has been banned by the World Anti-Doping Agency under the S0 category of non-exempt substances. BPC-157 has been widely used both by athletes and among the general public, mainly for recovery from injury or stimulating healing in chronic conditions, but there is as yet only very limited human trial data on efficacy and only a few preliminary safety studies. Human studies of BPC-157 remain scarce; a 2025 literature review identified limited clinical evidence, including a retrospective study of 12 patients with knee pain and a Phase I trial in healthy volunteers whose results were not submitted. Use of BPC-157 is discouraged by health authorities and it has been controlled as a prescription medicine in several jurisdictions such as New Zealand and Australia, despite not actually being available for prescription.

The nucleotide sequence of the human gene for proopiomelanocortin (POMC) was characterized in 1980. The POMC gene codes for endogenous opioids such as β-endorphin and γ-endorphin. The human gene for the enkephalins was isolated and its sequence described in 1982. The human gene for dynorphins (originally called the "Enkephalin B" gene because of sequence similarity to the enkephalin gene) was isolated and its sequence described in 1983. The PNOC gene encoding prepronociceptin, which is cleaved into nociceptin and potentially two additional neuropeptides. Adrenorphin, amidorphin, and leumorphin were discovered in the 1980s. The endomorphins were discovered in the 1990s. Opiorphin and spinorphin, enkephalinase inhibitors (i.e., prevent the metabolism of enkephalins). Hemorphins, hemoglobin-derived opioid peptides, including hemorphin-4, valorphin, and spinorphin, among others. While not peptides, codeine and morphine are also produced in the human body.

=== Transduction === Upon activation by dynorphin, KORs bind to pertussis toxin-sensitive heterotrimeric Gαi proteins, initiating a pattern of signaling events within the cell, including inhibition of adenylate cyclase activity, increase in K+ conductance, decrease in calcium conductance, emptying of intracellular calcium storage. KOR activation is coupled to the G protein Gi/G0, which subsequently increases phosphodiesterase activity. Phosphodiesterases break down cAMP, producing an inhibitory effect in neurons. KORs also couple to inward-rectifier potassium and to N-type calcium ion channels. Studies have also shown that agonist-induced stimulation of the KOR, like other G-protein coupled receptors, can result in the activation of mitogen-activated protein kinases (MAPK). These include extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinases, and c-Jun N-terminal kinases.

Warfarin: Since both tigecycline and warfarin bind to serum or plasma proteins, there is potential for protein-binding interactions, such that one drug will have more effect than the other. Although dose adjustment is not necessary, INR and prothrombin time should be monitored if given concurrently. Oral contraceptives: Effectiveness of oral contraceptives are decreased with concurrent use due to reduction in the concentration levels of oral contraceptives. However, the mechanism behind these drug interactions have not been fully analyzed.

Sources: en.wikipedia.org

Frequently asked questions

What is BPC-157 made of?

It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.

Is BPC-157 a hormone or a drug?

It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.

How much human evidence exists?

Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.

What is BPC-157?

BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.

Network